Basic Materials
Neogen Chemicals Limited (NSE: NEOGEN) gains 5% intraday, nears resistance
Neogen Chemicals Limited (NSE: NEOGEN) stock moves up 5% intraday to ₹1989.9, approaching resistance at ₹2007 in the Specialty Chemicals sector.
Neogen Chemicals Limited (NEOGEN) gained +5% intraday to near resistance at ₹2007. The stock is testing the 6-month resistance trendline but has not cleared it, despite today’s upward move. Neogen operates in the specialty chemicals segment of the basic materials sector, focusing on high-value chemicals and intermediates. Today’s move appears to be driven by technical factors rather than sector momentum, as there is no accompanying news or filing from the company.
Technical setup — trendlines & DMA
Currently, NEOGEN is approaching its 6-month resistance trendline, which stands at ₹2006.76, just 0.85% above today’s price. The stock has broken below the 6-month support trendline, which ends at ₹2014.72, indicating some weakness. However, the 50-day moving average (DMA) of ₹1778.2 is above the 200-DMA of ₹1421.2, signaling a bullish trend. NEOGEN is trading in the upper third of its 52-week range, suggesting that a significant portion of its potential upside may already be priced in.
Snapshot: ₹1,989.90 on 2026-06-30 (chart frozen at publication)
Fundamentals & business context
With a PE ratio of 173.2 and profit margins at 3.3%, NEOGEN’s valuation appears stretched relative to its current earnings, especially given its revenue CAGR of 9.3% over the past five years. The company’s institutional ownership of 21.4% suggests that while some smart money is invested, the overall fundamental picture is mixed. There is no new NSE catalyst today driving the move, reinforcing the technical nature of today’s price action.
Algorithmic scorecard
NEOGEN’s algorithmic scorecard reflects a technically strong but fundamentally weak profile. The strongest technical signals include the bullish trend indicated by the 50-DMA being above the 200-DMA and the bullish sentiment over the last 30 days, with 20 up days versus 8 down days. On the fundamental side, the consistent revenue growth every year and the acceptable debt levels (D/E of 0.76) are positives. However, the declining profit CAGR of -16.8% and the negligible dividend yield of 0.05% are significant risks that investors should consider.
Company outlook
Management provided forward guidance indicating sequential revenue growth in the battery chemicals business, with the majority of sales expected in the second half of the year. For FY27, standalone revenue is guided to be in the range of INR 875 to INR 950 crore, excluding battery chemicals revenue. The tentative target for FY28 revenue is around INR 1,100 crore plus, with potential for additional investment in areas like organolithium, semiconductor, flavor fragrance, or CSM needs. Expected consolidated revenue by FY29 is projected to be in the range of INR 3,700 to INR 4,200 crore. Key plans include the completion of the Dahej Phase 1 project by February 2027 and Pakhajan Phase 2 by March 2027, along with a strategic partnership with Japan’s Morita, involving an equity contribution of $20 million towards the joint venture expected during H1FY27. Additionally, the company plans capacity expansions and technology integrations, including the addition of 500 metric tons of intermediate salt capacity at Dahej.
Get all details on NEOGEN — P&L, peers, shareholding and more on TradeAlone.
Basic Materials
Valiant Organics Limited (valiantorg) Announces Details of Annual General Meeting FY 2025–26
Valiant Organics Limited (VALIANTORG) shares insights from its Annual General Meeting FY 2025–26, highlighting financial performance and strategic initiatives.
Valiant Organics Limited (VALIANTORG) is set to hold its Annual General Meeting (AGM) for FY 2025–26 on September 2026. This meeting will provide shareholders with a comprehensive overview of the company’s financial performance and strategic initiatives for the past fiscal year. Valiant Organics Limited, one of the largest chlorophenol derivatives manufacturers globally, has a diversified product range and a robust business model that spans multiple industries including pharmaceuticals, dyes, pigments, and agrochemicals.
Company Overview
Incorporated in 1984, Valiant Organics Limited is headquartered in Mumbai, India. The company specializes in manufacturing and marketing specialty chemicals, with key chemistries including chlorination, hydrogenation, ammonolysis, acetylation, sulphonation, and methoxylation. With a total production capacity of 80,000 TPA and over 900 employees, the company operates six manufacturing units across five locations, including five zero liquid discharge plants.
Financial Highlights
The company’s consolidated financial performance has shown steady growth. For FY 2025–26, the operational revenue stood at INR 912 Cr, with an EBITDA margin of 14.58%. The EBITDA for the year was INR 133 Cr, and the PAT margin was 8.60%. The company’s net debt to equity ratio improved, reflecting a strengthened balance sheet. The return on capital employed (ROCE) and return on equity (ROE) also indicate robust financial health.
As a result of the AGM, shareholders will gain insights into Valiant Organics Limited’s strategic direction, including future growth plans and operational efficiencies. The meeting will also highlight the company’s diversified client base and its strategic location advantages, which contribute to its competitive edge in the market.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Valiant Organics Limited
Valiant Organics Limited belongs to the Basic Materials › Chemicals sector. Here’s a quick read on where the business and the stock stand today.
Valiant gains 45.1% over three months and trades near its 52-week highs. Thin margins at 7.1% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Revenue contracts at -11.1% CAGR. That signals structural headwinds, not a short-term blip. Buyers show up with 1.6x the volume of sellers. Moreover, they dominated on 18 of recent sessions versus 12 for sellers — a healthy accumulation pattern. The stock rises 45.1% in three months. Yet revenue grows at only -11.1% and the PEG stands at 99.00. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of Valiant Organics Limited.
ANURAS
Anupam Rasayan India Limited Completes Acquisition of Bliss GVS Pharma, Marks Third Strategic Step
Anupam Rasayan India Limited (ANURAS) completes acquisition of Bliss GVS Pharma, marking third strategic step towards building an integrated global pharma pl.
Anupam Rasayan India Limited (BSE: 543275, NSE: ANURAS), one of India’s leading custom synthesis and specialty chemical companies, has concluded the acquisition of a 48.2% controlling stake in Bliss GVS Pharma Limited at ₹299 per share, marking its third strategic inorganic transaction and expanding its presence into finished dosage formulations.
Strategic Milestone
The acquisition, undertaken through Mates Visa Consultancy, a wholly owned subsidiary of Anupam Rasayan, follows the definitive agreement signed on May 23, 2026, and the subsequent completion of the mandatory open offer process. With the acquisition now finalized, Bliss GVS Pharma becomes an integral part of Anupam Rasayan’s expanding portfolio of businesses across specialty chemicals and pharmaceuticals.
Financial and Operational Synergy
The transaction has been funded through a combination of a ₹300 crore term loan and approximately ₹1,450 crore raised through non-controlling, non-voting instruments from a group of financial investors led by Bain Capital and including Trust Group and Investec. The financing structure enables Anupam Rasayan to fund the acquisition while preserving balance-sheet capacity for future growth and expansion.
Future Growth Prospects
On the acquisition, Mr. Anand Desai, Managing Director of Anupam Rasayan India Ltd., said, “We are pleased to announce the successful completion of the acquisition of Bliss GVS Pharma. This transaction marks an important milestone in our long-term strategy to build a diversified, integrated and innovation-led global pharmaceutical platform. The acquisition strengthens our presence in finished pharmaceutical formulations and complements Anupam Rasayan’s expertise in key starting materials, intermediates and specialty chemicals.”
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Anupam Rasayan India Limited
Anupam Rasayan India Limited belongs to the Basic Materials › Specialty Chemicals sector. Here’s a quick read on where the business and the stock stand today.
Anupam moves sideways over three months, with neither buyers nor sellers taking control. Thin margins at 6.9% leave limited room for error — any demand softness or cost spike hits the bottom line hard. No meaningful dividend — total return is entirely dependent on capital appreciation. Sellers drive 1.8x the volume of buyers. Furthermore, they controlled 17 of recent sessions versus 13 for buyers — a clear distribution signal. Revenue grows at 14.1% yet the PEG reaches 99.00 — expensive for that growth. Furthermore, the stock drops 6.1% in three months. Neither value nor momentum supports this setup. It needs an earnings beat or a price reset first. Check Fundamentals of Anupam Rasayan India Limited.
Aluminum
National Aluminium Company Limited (nationalum) Announces Record Dividend Payment for FY 2025-26
National Aluminium Company Limited (NATIONALUM) pays ₹1,083.06 crore dividend to Government of India for FY 2025-26, marking highest-ever payout.
National Aluminium Company Limited (NATIONALUM) has made headlines today by announcing a record dividend payment of ₹1,083.06 crore to the Government of India for FY 2025-26. This marks the highest-ever dividend paid by the company, reflecting its robust financial performance for the year. The dividend cheque was handed over to Shri G. Kishan Reddy, Hon’ble Union Minister of Coal & Mines, Government of India, during an Investor Roadshow on Angul Aluminium Park held in Kolkata today.
Record-Breaking Dividend
The total dividend paid by NATIONALUM for FY 2025-26 amounts to ₹2,112.12 crore, which includes three interim dividends and a final dividend. This significant payout underscores the company’s commitment to returning value to its shareholders and the government. The robust performance in FY 2025-26 saw a Profit After Tax (PAT) of ₹5,815.76 crore, highlighting the company’s strong financial health and operational efficiency.
Strategic Investment Roadshow
The announcement came during an Investor Roadshow organized by NATIONALUM in association with Odisha Industrial Infrastructure Development Corporation (IDCO) at Angul Aluminium Park in Kolkata. The event aimed to showcase investment opportunities in downstream and value-added aluminium manufacturing. Shri Jagdish Arora, Director (P&T), NATIONALUM, welcomed the attendees and emphasized the investor-friendly ecosystem that supports employment generation and industrial growth.
As a result, the Angul Aluminium Park is poised to become a pivotal platform for establishing and expanding aluminium-based manufacturing operations, fostering innovation, and contributing to India’s vision of building a self-reliant and developed nation.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of National Aluminium Company Limited
National Aluminium Company Limited belongs to the Basic Materials › Aluminum sector. Here’s a quick read on where the business and the stock stand today.
National posts a 2.8% three-month gain, but softens in the last few weeks. The PEG of 0.16 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. Industry-leading margins of 34.9% reflect exceptional pricing power and operational efficiency. The stock gives back 11.6% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Revenue grows at 7.8% and profits at 59.3%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of National Aluminium Company Limited.
-
Healthcare1 day agoLupin Limited (lupin) Receives Tentative FDA Approval for Apixaban Oral Suspension
-
Consumer Defensive1 day agoRadico Khaitan Limited Expands Global Reach: Indian Luxury Whisky Brands Land in the Home of Scotch
-
Banks - Regional1 day agoIndusind Bank Limited Launches Dedicated Banking Vertical for India’s Growing Global Capability Centres
-
Capital Markets1 day agoIndian Energy Exchange Limited Expands Energy Markets Footprint
-
RATEGAIN1 day agoRategain Travel Technologies Limited (NSE: Rategain) Appoints Chetan Garg as Chief Financial Officer
-
Credit Services1 day agoMoneyboxx Finance Limited (moneyboxx) Raises ₹60 Crore Via Ncds
-
Credit Services1 day agoIndian Railway Finance Corporation Limited Signs Rs 4,200 Crore Loan Agreement with DVC for Renewable Energy Projects
-
Healthcare1 day agoSun Pharmaceutical Industries Limited (sunpharma) Secures Global Licensing for Lerodalcibep, a PCSK9 Inhibitor
